Barclays PLC Has $1.44 Million Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN)

Barclays PLC boosted its stake in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 295.8% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 56,217 shares of the company's stock after purchasing an additional 42,012 shares during the period. Barclays PLC owned about 0.12% of Enliven Therapeutics worth $1,435,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the stock. FMR LLC raised its stake in shares of Enliven Therapeutics by 10.6% during the 3rd quarter. FMR LLC now owns 6,296,179 shares of the company's stock worth $160,804,000 after purchasing an additional 601,611 shares in the last quarter. Janus Henderson Group PLC raised its holdings in Enliven Therapeutics by 43.0% in the 3rd quarter. Janus Henderson Group PLC now owns 1,041,724 shares of the company's stock worth $26,611,000 after acquiring an additional 313,019 shares during the period. State Street Corp lifted its position in Enliven Therapeutics by 2.9% during the 3rd quarter. State Street Corp now owns 745,944 shares of the company's stock worth $19,051,000 after acquiring an additional 21,018 shares during the last quarter. First Turn Management LLC lifted its position in Enliven Therapeutics by 29.5% during the 3rd quarter. First Turn Management LLC now owns 535,092 shares of the company's stock worth $13,666,000 after acquiring an additional 121,849 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in Enliven Therapeutics by 10.4% during the third quarter. Charles Schwab Investment Management Inc. now owns 255,277 shares of the company's stock valued at $6,520,000 after acquiring an additional 24,043 shares during the period. Institutional investors and hedge funds own 95.08% of the company's stock.

Enliven Therapeutics Price Performance

Shares of NASDAQ ELVN traded down $0.34 during mid-day trading on Friday, hitting $22.37. The company had a trading volume of 255,845 shares, compared to its average volume of 170,189. Enliven Therapeutics, Inc. has a 12 month low of $10.90 and a 12 month high of $30.03. The firm has a market cap of $1.09 billion, a P/E ratio of -11.77 and a beta of 1.02. The business's 50-day simple moving average is $25.58 and its 200-day simple moving average is $24.28.

Analyst Ratings Changes

ELVN has been the topic of a number of recent analyst reports. Robert W. Baird lifted their price objective on Enliven Therapeutics from $32.00 to $40.00 and gave the stock an "outperform" rating in a research note on Friday, November 15th. HC Wainwright reaffirmed a "buy" rating and issued a $37.00 price target on shares of Enliven Therapeutics in a research report on Tuesday, October 1st. Finally, BTIG Research assumed coverage on Enliven Therapeutics in a report on Friday, December 13th. They set a "buy" rating and a $42.00 price target for the company. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, Enliven Therapeutics has an average rating of "Buy" and an average price target of $38.25.

Insider Buying and Selling at Enliven Therapeutics

In other news, CFO Benjamin Hohl sold 5,250 shares of Enliven Therapeutics stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $24.89, for a total transaction of $130,672.50. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Samuel Kintz sold 2,730 shares of the company's stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $27.50, for a total transaction of $75,075.00. Following the completion of the sale, the chief executive officer now directly owns 1,033,793 shares in the company, valued at approximately $28,429,307.50. The trade was a 0.26 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 124,945 shares of company stock valued at $3,478,624 in the last quarter. Corporate insiders own 29.20% of the company's stock.

Enliven Therapeutics Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.